GLAXOSMITHKLINE PLC ORD 25P chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 9.28
Dividend & Yield0.86£ (6.18%)
Beta 0.29
Market capitalization 57.62B
Operating cash flow 10.51B
ESG Scores 18.9

Company description

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Sector: Healthcare - Industry: Drug Manufacturers—General

Financial Ratios
Quick Ratio0.54
Working Capital-0.88
Return On Equity0.29
Debt To Equity1.31
Fixed Asset Ratio0.54
Fixed Interest Cover10.28

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 131M 263M 225M 284M
Total Cashflows From Investing Activities -1.55B -5.35B 2.16B -1.78B
Net Borrowings 8.12B 3.52B -4.23B -2.21B
Total Cash From Financing Activities -6.39B -1.84B -10.13B -7.59B
Change To Operating Activities 18M -259M 1.06B 670M
Issuance Of Stock 74M 51M 29M 21M
Net Income 3.62B 4.64B 5.75B 4.38B
Change In Cash 487M 744M 431M -1.44B
Effect Of Exchange Rate 8M -82M -39M -29M
Total Cash From Operating Activities 8.42B 8.02B 8.44B 7.95B
Depreciation 1.86B 2.33B 2.11B 2.15B
Change To Account Receivables -429M -32M -224M -782M
Other Cashflows From Financing Activities -10.66B -1.45B -1.95B -1.4B
Change To Netincome 3.17B 769M -838M 993M
Capital Expenditures -1.34B -1.26B -1.23B -1.17B

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 3.8B 4.41B 4.68B 4.88B
Income Before Tax 4.8B 6.22B 6.97B 5.44B
Net Income 3.62B 4.64B 5.75B 4.38B
Selling General Administrative 9.5B 10.96B 10.5B 10.19B
Gross Profit 21.11B 22.96B 23.21B 22.66B
Ebit 7.5B 8.2B 8.44B 7.97B
Operating Income 7.5B 8.2B 8.44B 7.97B
Interest Expense -756M -877M -860M -775M
Income Tax Expense 754M 953M 580M 346M
Total Revenue 30.82B 33.75B 34.1B 34.11B
Cost Of Revenue 9.71B 10.79B 10.89B 11.45B
Total Other Income ExpenseNet -2.69B -1.98B -1.47B -2.52B
Net Income From Continuing Ops 4.05B 5.27B 6.39B 5.1B
Net Income Applicable To Common Shares 3.62B 4.64B 5.75B 4.38B

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 54.39B 61.34B 59.62B 57.76B
Total Stockholder Equity 3.78B 11.4B 14.59B 15.05B
Other Current Liabilities 5.23B 4.78B 5.4B 5.56B
Total Assets 58.07B 79.69B 80.43B 79.1B
Common Stock 1.34B 1.35B 1.35B 1.35B
Other Current Assets 658M 941M 195M 133M
Retained Earnings -2.7B 5.05B 7.29B 8.75B
Treasury Stock 2.05B 1.83B 2.67B 1.66B
Cash 3.87B 4.71B 6.29B 4.27B
Total Current Liabilities 22.49B 24.05B 22.15B 23.67B
Other Stockholder Equity 2.05B 1.83B 2.67B 1.66B
Property, Plant, and Equipment 11.06B 11.31B 11.01B 10.67B
Total Current Assets 16.93B 19.49B 20.25B 18.67B
Net Tangible Assets -19.21B -30.11B -25.83B -25.58B
Net Receivables 5.95B 6.44B 6.86B 7.48B
Accounts Payable 3.65B 4.14B 4.36B 4.54B


Insider Transactions

Here are the insider transactions of stock shares related to GLAXOSMITHKLINE PLC ORD 25P:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Jackson (S)Bought at price 14.86 per share.D2022-10-119
Jackson (S)D2022-10-119
Jackson (S)Bought at price 14.86 per share.D2022-10-119
Jackson (S)D2022-10-119
Jackson (S)Bought at price 14.88 per share.D2022-10-11287
Jackson (S)Bought at price 14.88 per share.D2022-10-11154
Conrad (D)Bought at price 14.88 per share.D2022-10-117
Connor (Roger G)Bought at price 14.86 per share.D2022-10-119
Connor (Roger G)D2022-10-119
Connor (Roger G)Bought at price 14.88 per share.D2022-10-112.83k
Ford (J)Bought at price 14.86 per share.D2022-10-1110
Ford (J)D2022-10-1110
Walmsley (Emma Natasha)D2022-10-1110
Walmsley (Emma Natasha)Bought at price 14.88 per share.D2022-10-114.44k
Walmsley (Emma Natasha)Bought at price 14.86 per share.D2022-10-1110
Waterhouse (D)Bought at price 14.86 per share.D2022-10-119
Waterhouse (D)D2022-10-119
Waterhouse (D)Bought at price 14.88 per share.D2022-10-11280
Wood (T)Bought at price 14.88 per share.D2022-10-11327
Thomson (Phil C)Bought at price 14.86 per share.D2022-10-119
Thomson (Phil C)D2022-10-119
Thomson (Phil C)Bought at price 14.88 per share.D2022-10-111.07k
Thomson (Phil C)Bought at price 14.88 per share.D2022-10-11119
Whyte (Victoria L)Bought at price 14.86 per share.D2022-10-119
Whyte (Victoria L)D2022-10-119
Simard (Regis)Bought at price 14.86 per share.D2022-10-119
Simard (Regis)D2022-10-119
Simard (Regis)Bought at price 14.88 per share.D2022-10-11990
Redfern (David S)Bought at price 14.86 per share.D2022-10-1110
Redfern (David S)D2022-10-1110
Redfern (David S)Bought at price 14.88 per share.D2022-10-114.15k
Redfern (David S)Bought at price 14.63 per share.D2022-10-10488
Simard (Regis)Bought at price 14.63 per share.D2022-10-10390
Mackay (Iain James)Bought at price 14.63 per share.D2022-10-101.92k
Mackay (Iain James)Bought at price 14.63 per share.D2022-10-101.54k
Miels (Luke)Bought at price 14.63 per share.D2022-10-10682
Ford (J)Bought at price 14.63 per share.D2022-10-10416
Connor (Roger G)Bought at price 14.63 per share.D2022-10-10517
Conrad (D)Bought at price 14.63 per share.D2022-10-10324
Jackson (S)Bought at price 14.63 per share.D2022-10-10191
Thomson (Phil C)Bought at price 14.63 per share.D2022-10-10292
Waterhouse (D)Bought at price 14.63 per share.D2022-10-10286
Walmsley (Emma Natasha)Bought at price 14.63 per share.D2022-10-102.24k
Walmsley (Emma Natasha)Bought at price 14.63 per share.D2022-10-107.96k
Walmsley (Emma Natasha)Bought at price 14.88 per share.D2022-10-0625
Waterhouse (D)Bought at price 14.88 per share.D2022-10-0663
Thomson (Phil C)Bought at price 14.88 per share.D2022-10-0648
Whyte (Victoria L)Bought at price 14.84 per share.D2022-10-0631
Whyte (Victoria L)Bought at price 14.84 per share.D2022-10-061.05k
Whyte (I W)Bought at price 14.88 per share.D2022-10-0658
Conrad (D)Bought at price 14.88 per share.D2022-10-066

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to GLAXOSMITHKLINE PLC ORD 25P. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on GLAXOSMITHKLINE PLC ORD 25P

Here is the result of two systematic investment strategies applied to GLAXOSMITHKLINE PLC ORD 25P. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on GLAXOSMITHKLINE PLC ORD 25P

The following chart shows the equity curve of the two systematic investment strategies applied to GLAXOSMITHKLINE PLC ORD 25P:

GLAXOSMITHKLINE PLC ORD 25P automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 4.73% on the backtest period.

Performance at glance

Performance

4.73 %

Latent gain

503.8 £

Invested capital

10650.0 £

Annualized return

1.15 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on GLAXOSMITHKLINE PLC ORD 25P

This is the result of two momentum investment strategies applied to GLAXOSMITHKLINE PLC ORD 25P. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on GLAXOSMITHKLINE PLC ORD 25P

The following chart shows all the entries opened by the momentum investment system on GLAXOSMITHKLINE PLC ORD 25P:

GLAXOSMITHKLINE PLC ORD 25P momentum entries
  • The first momentum investment strategy would give 10.71% of return on GLAXOSMITHKLINE PLC ORD 25P. That represents 925.2£ of latent gain with 8635.2£ of employed capital.
  • The second momentum investment strategy would give 6.41% of return on GLAXOSMITHKLINE PLC ORD 25P. That represents 575.8£ of latent gain with 8984.6£ of employed capital.
Performance at glance (1Q Momentum)

Performance

10.71 %

Latent gain

925.2 £

Invested capital

8635.2 £

Annualized return

9.94 %
Performance at glance (2Q Momentum)

Performance

6.41 %

Latent gain

575.8 £

Invested capital

8984.6 £

Annualized return

1.76 %

Momentum equity curve on GLAXOSMITHKLINE PLC ORD 25P

The following chart shows the equity curve of the two momentum strategies applied to GLAXOSMITHKLINE PLC ORD 25P:

GLAXOSMITHKLINE PLC ORD 25P momentum equity

Note: the dividends potentially given by GLAXOSMITHKLINE PLC ORD 25P are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on GLAXOSMITHKLINE PLC ORD 25P

The following chart shows the employed capital evolution of the two momentum strategies on GLAXOSMITHKLINE PLC ORD 25P since the beginning:

GLAXOSMITHKLINE PLC ORD 25P

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on GLAXOSMITHKLINE PLC ORD 25P

Buy the dip entry openings on GLAXOSMITHKLINE PLC ORD 25P

GLAXOSMITHKLINE PLC ORD 25P

The performance achieved by the robo-advisor on GLAXOSMITHKLINE PLC ORD 25P is 21.07%. That represents 1109.2$ of latent gain with 5264.4£ of employed capital. The following chart shows GLAXOSMITHKLINE PLC ORD 25P stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of GLAXOSMITHKLINE PLC ORD 25P, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

21.07 %

Latent gain

1109.2 £

Invested capital

5264.4 £

Annualized return

9.94 %

Equity curve of the strategy applied to GLAXOSMITHKLINE PLC ORD 25P

The following chart shows the result of the investment strategy applied to GLAXOSMITHKLINE PLC ORD 25P:

GLAXOSMITHKLINE PLC ORD 25P

Note: the dividends potentially given by GLAXOSMITHKLINE PLC ORD 25P are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on GLAXOSMITHKLINE PLC ORD 25P

The following chart shows the employed capital evolution since the beginning of the investment strategy on GLAXOSMITHKLINE PLC ORD 25P:

GLAXOSMITHKLINE PLC ORD 25P

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on GLAXOSMITHKLINE PLC ORD 25P

In this section, I will compare the three previous investment strategies applied to GLAXOSMITHKLINE PLC ORD 25P.

Equity curve comparison on GLAXOSMITHKLINE PLC ORD 25P

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

GLAXOSMITHKLINE PLC ORD 25P investment strategy comparison

Employed capital comparison on GLAXOSMITHKLINE PLC ORD 25P

GLAXOSMITHKLINE PLC ORD 25P investment comparison

Performance comparison on GLAXOSMITHKLINE PLC ORD 25P

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 4.73% 503.8£ 10650.0£ 1.15%
Momentum 1 quarter 10.71% 925.2£ 8635.2£ 2.76%
Momentum 2 quarters 6.41% 575.8£ 8984.6£ 1.76%
Non-directional 21.07% 1109.2£ 5264.4£ 9.94%
Annualized return comparison

Automatic investment

1.15 %

Momentum 1Q

1.76 %

Momentum 2Q

1.76 %

Non-directional

9.94 %

Correlated stocks

Here are the most positively and negatively correlated stocks with GLAXOSMITHKLINE PLC ORD 25P:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between GLAXOSMITHKLINE PLC ORD 25P and the other stocks. There may be false positives or some missing correlated stocks. If the price of GLAXOSMITHKLINE PLC ORD 25P does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name GLAXOSMITHKLINE PLC ORD 25P
Country United Kingdom
City Brentford
Address 980 Great West Road
Phone 44 20 8047 5000
Website www.gsk.com
FullTime employees 90096
Industry Drug Manufacturers—General
Sector Healthcare
Exchange XLON
Ticker GSK.XLON
Market www.londonstockexchange.com

GLAXOSMITHKLINE PLC ORD 25P ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 2.8
Peer Environment Performance 2.0330864197531
Environment Percentile unknown
Palm Oil no
Nuclear no
Fur Leather no
GMO no
Coal no
Pesticides no
Animal Testing yes

Social scores

Social ESG Factors Scores
Social Score 10.2
Peer Social Performance 14.299012345679
Social Percentile unknown
Highest Controversy 2
Peer Highest Controversy Performance 1.8780487804878
Adult no
Gambling no
Alcoholic no
Tobacco no
Catholic yes
Controversial Weapons no
Small Arms no
Military Contract no
Peer Count yes

Related Controversy: Customer Incidents


Governance scores

Governance ESG Factors Scores
Governance Score 5.8
Peer Governance Performance 8.8141975308642
Governance Percentile unknown

ESG at glance
Total ESG Scores: 18.9
Environment Score: 2.8
Social Score: 10.2
Governance Score: 5.8

ESG Performance: UNDER_PERF

Peer Group: Pharmaceuticals

Peer Esg Score Performance: 25.306097560976

Rating Year: 2022

Rating Month: 8

Max Age: 86400

Percentile: 22